research Alopecia Areata Flare Patterns in Children and Young Adults on Systemic Tofacitinib
Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
Search
for
Sort by
Research
240-270 / 1000+ results 
research A Promising Efficacy of Tofacitinib in an Adult Patient with Alopecia Areata
Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
research Single-Cell Transcriptomics Reveals a Senescence-Associated IL-6/CCR6 Axis Driving Radiodermatitis
Blocking certain immune signals can reduce skin damage from radiation therapy.
research Scarring Alopecia Is Driven by the Collapse of EGFR-Protected JAK-STAT1-Sensitive Stem Cell Immune Privilege
Cancer treatment drugs can cause permanent hair loss by damaging hair follicle stem cells, but a specific inhibitor might reverse this effect.
research Alopecia Areata in Children: An Overview of Clinical Features and Recent Treatment Options
New treatments for child hair loss due to immune issues are effective but not yet officially approved.
research Annual Convention in the Time of COVID: The 2020 Dermatology Nurses' Association Meeting
The convention discussed various skin conditions and treatments, and highlighted the importance of vaccinations for patients on immune-altering medications.
research Updates From 2021 Virtual Dermatology Nurses' Association Convention
The convention discussed various skin conditions, treatments, and the importance of continuous learning in dermatology nursing.
research Various Applications of Tofacitinib and Ruxolitinib in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
research Janus Kinase Inhibitors Versus Other Biological Treatments in Alopecia Areata
Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
research Tumor Necrosis Factor Inhibitors and Janus Kinase Inhibitors in the Treatment of Cicatricial Alopecia: A Systematic Review
Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients
Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
research Janus Kinase Inhibitors For Alopecia Areata
JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.
research Janus Kinase Inhibitors for the Use of Alopecia Areata: A Promising Therapeutic of the Future
JAK inhibitors show promise as a future treatment for hair loss.
research Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib
Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.
research Janus Kinase Inhibitors for Alopecia Areata
JAK inhibitors offer new hope for treating severe alopecia areata.
research Janus Kinase Inhibitor as a Therapeutic Option in Alopecia Areata: Case Report
JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.
research Are Janus Kinase (JAK) Inhibitors Beneficial in the Treatment of Androgenic Alopecia?
JAK inhibitors do not improve hair regrowth in androgenic alopecia but may prevent further hair loss.
research Topical Janus Kinase Inhibitors for the Treatment of Pediatric Alopecia Areata
Topical JAK inhibitors may help children with alopecia areata regrow hair.
research Janus Kinase Inhibition in Down Syndrome: Two Cases of Therapeutic Benefit for Alopecia Areata
JAK inhibitors helped treat hair loss in two people with Down syndrome.
research Janus Kinase (JAK) Inhibitors in Treating Alopecia Areata (AA)
JAK inhibitors may help treat alopecia areata and promote hair regrowth.
research Use of Intramuscular Triamcinolone Acetonide in Intermediate Responders to Janus Kinase Inhibition for Alopecia Areata: Case Report
IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Janus Kinase Inhibitor as a Therapeutic Option in Alopecia Areata: Case Report
Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.
research Rebound Effect Associated with JAK Inhibitor Use in the Treatment of Alopecia Areata
Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
research Response to Effectiveness of Dutasteride in a Large Series of Patients with Frontal Fibrosing Alopecia in Real Clinical Practice
The authors suggest that 5-α-reductase inhibitors, like dutasteride, are effective in treating frontal fibrosing alopecia and should be the first-line treatment, with other options for severe cases. They also recommend further research on Janus kinase inhibitors.
research Clinical Investigation of JAK Inhibitor Tofacitinib in Scarring Alopecias
Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.
research Observation and Consideration on Using of JAKi in Clinical Trials in Times of COVID-19
Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.
research Inhibiting Janus Kinases to Treat Alopecia Areata
JAK inhibitors might help treat alopecia areata.
research Screening for Latent Infectious Disease in Patients with Alopecia Areata Before Initiating JAK Inhibitors Therapy: A Single-Center Real-World Retrospective Study
Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.